<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="401">
  <stage>Registered</stage>
  <submitdate>6/10/2003</submitdate>
  <approvaldate>6/10/2003</approvaldate>
  <nctid>NCT00070655</nctid>
  <trial_identification>
    <studytitle>Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS)</studytitle>
    <scientifictitle>The AMADEUS Trial, A Multicenter, Randomized, Open-label, Assessor Blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Idraparinux (SR34006) With Adjusted-dose Oral Vitamin-K Antagonists in the Prevention of Thromboembolic Events in Patients With Atrial Fibrillation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>SR34006</secondaryid>
    <secondaryid>EFC5134</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Atrial Fibrillation</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - SR34006 (idraparinux sodium) Injection
Treatment: drugs - vitamin K antagonist (warfarin or acenocoumarol) tablets

Treatment: drugs: SR34006 (idraparinux sodium) Injection


Treatment: drugs: vitamin K antagonist (warfarin or acenocoumarol) tablets


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Composite of all strokes and non-CNS systemic embolism.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Separate components of the primary study outcome.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  ECG-documented atrial fibrillation (AF) and an indication for long-term vitamin K
             antagonist (VKA) therapy based on the presence of at least one of the following risk
             factors:

               1. previous ischemic stroke, transient ischemic attack (TIA) or systemic embolism

               2. hypertension requiring drug treatment

               3. left ventricular dysfunction (left ventricular ejection fraction &lt;45% or
                  symptomatic congestive heart failure)

               4. age &gt;75 years

               5. age between 65-75 years plus diabetes mellitus, or

               6. age between 65-75 years plus symptomatic coronary artery disease (previous
                  myocardial infarction (MI) or angina pectoris)

          -  Written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Legal lower age limitations (country specific)

          -  Indication for VKA other than AF, including prosthetic heart valves, venous
             thromboembolism, and planned cardioversion

          -  Transient AF caused by a reversible disorder

          -  Active bleeding or high risk of bleeding

          -  Recent (&lt;15 days) or anticipated invasive procedures with potential for uncontrolled
             bleeding, including major surgery

          -  Participation in another pharmacotherapeutic study within the prior 30 days

          -  Creatinine clearance &lt;10 mL/min, severe hepatic disease, or bacterial endocarditis

          -  Uncontrolled hypertension: systolic blood pressure &gt; 180 mm Hg and/or diastolic blood
             pressure &gt; 110 mm Hg

          -  Pregnancy or childbearing potential without proper contraceptive measures

          -  Breastfeeding

          -  Any other contraindication listed in the labeling of warfarin or acenocoumarol</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>4673</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Bondi Junction, Cairns, Camperdown, Miranda, Perth</hospital>
    <hospital>Concord Repartiation General Hospital - Concord</hospital>
    <hospital> - South Australia, Tasmania, Victoria</hospital>
    <postcode> - Bondi Junction, Cairns, Camperdown, Miranda, Perth</postcode>
    <postcode> - Concord</postcode>
    <postcode> - South Australia, Tasmania, Victoria</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Newfoundland and Labrador</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Saskatchewan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Faaborg, Fredericia, Frederiksberg, Frederikshavn, Hellerup</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Herlev, Hillerod, Holstebro, Horsens, Kalundborg, Kobenhavn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Kolding, Nykobing Mors, Odense, Skive, Svendborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bourg En Bresse, Dreux, Lille, Marseille, Maubeuge, Mulhouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes, Nice, Paris, Poitiers, Rennes, Saint Denis</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint-Etienne, Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Cremona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Merate, Milano, Padova, Pavia, Piacenza, Reggio Emilia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Parma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rimini</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino, Treviso</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Varese</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Almelo, Amersfoort, Breda, Boxmeer, Delft, Dordrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Eindhoven, Enschede, Gorinchem, Gouda, Groningen, Harderwijk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Heerlen, Hilversum, Rotterdam, Sneek, Spijkenisse, Tiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Maastricht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland, Christchurch, Hastings</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Kielce, Krakow, Opole, Plock, Siedlce, Warszawa, Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cardiff</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Exeter, Dundee, Glasgow, Merseyside, Wirral</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Newscastle Upon Tyne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Wolverhampton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial will include patients who have a heart condition called atrial fibrillation.
      Atrial fibrillation is an abnormal rhythm (irregular beat) in the heart. Patients with atrial
      fibrillation have an increased chance for a blood clot to form in the heart and move to other
      blood vessels in the body and cause obstruction. This obstruction may damage tissue. For
      example, a blood clot plugging a vessel in the brain could cause a stroke. Therefore,
      patients with atrial fibrillation may be given anticoagulant (blood-thinning) tablets such as
      warfarin or acenocoumarol.

      The purpose of this study is to compare the safety and effectiveness of a new injectable
      anticoagulant drug that is administered once weekly, SR34006 with warfarin or acenocoumarol
      tablets.

      Assignment to either SR34006 Injection or vitamin K antagonist (warfarin or acenocoumarol)
      tablets will be purely by chance and will be known by both patients and their doctors.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00070655</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>ICD CSD</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>